{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:26:37Z","timestamp":1785788797104,"version":"3.56.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"39","license":[{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"1. Mildred-Scheel-Postdoctoral program of the Mildred Scheel Foundation"},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["DRSG-24-18"],"award-info":[{"award-number":["DRSG-24-18"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}],"id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}],"id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003287","name":"Rally Foundation","doi-asserted-by":"publisher","award":["Young Investigator Award"],"award-info":[{"award-number":["Young Investigator Award"]}],"id":[{"id":"10.13039\/100003287","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2019,9,26]]},"DOI":"10.1038\/s41388-019-0965-5","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T11:03:11Z","timestamp":1566558191000},"page":"6585-6598","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1571-7077","authenticated-orcid":false,"given":"Dong Hyuk","family":"Ki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1011-1954","authenticated-orcid":false,"given":"Felix","family":"Oppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5472-9847","authenticated-orcid":false,"given":"Adam D.","family":"Durbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7851-8617","authenticated-orcid":false,"given":"A. Thomas","family":"Look","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,23]]},"reference":[{"key":"965_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2165\/00148581-200709040-00005","volume":"9","author":"A Ferrari","year":"2007","unstructured":"Ferrari A, Bisogno G, Carli M. Management of childhood malignant peripheral nerve sheath tumor. Paediatr Drugs. 2007;9:239\u201348.","journal-title":"Paediatr Drugs."},{"key":"965_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S1474-4422(07)70075-3","volume":"6","author":"RE Ferner","year":"2007","unstructured":"Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol. 2007;6:340\u201351.","journal-title":"Lancet Neurol."},{"key":"965_CR3","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11060-006-9266-2","volume":"82","author":"C Hagel","year":"2007","unstructured":"Hagel C, Zils U, Peiper M, Kluwe L, Gotthard S, Friedrich RE, et al. Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol. 2007;82:187\u201392.","journal-title":"J Neurooncol."},{"key":"965_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2015.12.015","volume":"56","author":"T Valentin","year":"2016","unstructured":"Valentin T, Le Cesne A, Ray-Coquard I, Italiano A, Decanter G, Bompas E, et al. Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the French Sarcoma Group (GSF-GETO). Eur J Cancer. 2016;56:77\u201384.","journal-title":"Eur J Cancer."},{"key":"965_CR5","doi-asserted-by":"publisher","first-page":"7429697","DOI":"10.1155\/2017\/7429697","volume":"2017","author":"A Kim","year":"2017","unstructured":"Kim A, Stewart DR, Reilly KM, Viskochil D, Miettinen MM, Widemann BC. Malignant peripheral nerve sheath tumors state of the science: leveraging clinical and biological insights into effective therapies. Sarcoma. 2017;2017:7429697.","journal-title":"Sarcoma."},{"key":"965_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0092-8674(01)00245-8","volume":"104","author":"K Cichowski","year":"2001","unstructured":"Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001;104:593\u2013604.","journal-title":"Cell."},{"key":"965_CR7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/0092-8674(90)90150-D","volume":"63","author":"GA Martin","year":"1990","unstructured":"Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, et al. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990;63:843\u20139.","journal-title":"Cell."},{"key":"965_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/stem.170235","volume":"17","author":"DS Goodsell","year":"1999","unstructured":"Goodsell DS. The molecular perspective: the ras oncogene. Stem Cells. 1999;17:235\u20136.","journal-title":"Stem Cells."},{"key":"965_CR9","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1038\/ng.3095","volume":"46","author":"W Lee","year":"2014","unstructured":"Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46:1227\u201332.","journal-title":"Nat Genet."},{"key":"965_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nature13561","volume":"514","author":"T De Raedt","year":"2014","unstructured":"De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514:247\u201351.","journal-title":"Nature."},{"key":"965_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1172\/JCI60578","volume":"123","author":"WJ Jessen","year":"2013","unstructured":"Jessen WJ, Miller SJ, Jousma E, Wu J, Rizvi TA, Brundage ME, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest. 2013;123:340\u20137.","journal-title":"J Clin Invest."},{"key":"965_CR12","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.18632\/oncotarget.1609","volume":"5","author":"AL Watson","year":"2014","unstructured":"Watson AL, Anderson LK, Greeley AD, Keng VW, Rahrmann EP, Halfond AL, et al. Co-targeting the MAPK and PI3K\/AKT\/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. Oncotarget. 2014;5:1502\u201314.","journal-title":"Oncotarget."},{"key":"965_CR13","doi-asserted-by":"publisher","first-page":"35753","DOI":"10.18632\/oncotarget.7099","volume":"7","author":"J Varin","year":"2016","unstructured":"Varin J, Poulain L, Hivelin M, Nusbaum P, Hubas A, Laurendeau I, et al. Dual mTORC1\/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. Oncotarget. 2016;7:35753\u201367.","journal-title":"Oncotarget."},{"key":"965_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1158\/1078-0432.CCR-12-1067","volume":"19","author":"M Endo","year":"2013","unstructured":"Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, et al. Prognostic significance of AKT\/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. 2013;19:450\u201361.","journal-title":"Clin Cancer Res."},{"key":"965_CR15","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/onc.2016.269","volume":"36","author":"DH Ki","year":"2017","unstructured":"Ki DH, He S, Rodig S, Look AT. Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors. Oncogene. 2017;36:1058\u201368.","journal-title":"Oncogene."},{"key":"965_CR16","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/ejhg.2011.113","volume":"19","author":"DG Evans","year":"2011","unstructured":"Evans DG, O\u2019Hara C, Wilding A, Ingham SL, Howard E, Dawson J, et al. Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet. 2011;19:1187\u201391.","journal-title":"Eur J Hum Genet"},{"key":"965_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-6-18","volume":"6","author":"TA Duong","year":"2011","unstructured":"Duong TA, Sbidian E, Valeyrie-Allanore L, Vialette C, Ferkal S, Hadj-Rabia S, et al. Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France. Orphanet J Rare Dis. 2011;6:18.","journal-title":"Orphanet J Rare Dis."},{"key":"965_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.nec.2008.07.004","volume":"19","author":"G Gupta","year":"2008","unstructured":"Gupta G, Mammis A, Maniker A. Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am. 2008;19:533\u201343.","journal-title":"Neurosurg Clin N Am."},{"key":"965_CR19","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1245\/s10434-011-1978-7","volume":"19","author":"CC Stucky","year":"2012","unstructured":"Stucky CC, Johnson KN, Gray RJ, Pockaj BA, Ocal IT, Rose PS, et al. Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol. 2012;19:878\u201385.","journal-title":"Ann Surg Oncol."},{"key":"965_CR20","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1242\/dmm.009779","volume":"5","author":"J Shin","year":"2012","unstructured":"Shin J, Padmanabhan A, de Groh ED, Lee JS, Haidar S, Dahlberg S, et al. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. Dis Model Mech. 2012;5:881\u201394.","journal-title":"Dis Model Mech."},{"key":"965_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/978-3-319-30654-4_22","volume":"916","author":"AD Durbin","year":"2016","unstructured":"Durbin AD, Ki DH, He S, Look AT. Malignant peripheral nerve sheath tumors. Adv Exp Med Biol. 2016;916:495\u2013530.","journal-title":"Adv Exp Med Biol."},{"key":"965_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-15183-1","volume":"7","author":"AS Brohl","year":"2017","unstructured":"Brohl AS, Kahen E, Yoder SJ, Teer JK, Reed DR. The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Sci Rep. 2017;7:14992.","journal-title":"Sci Rep."},{"key":"965_CR23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2967\/jnmt.117.199927","volume":"46","author":"M Charest","year":"2017","unstructured":"Charest M, Pressacco J, Thomas-Gittens J. Malignant peripheral nerve sheath tumours of the pericardium in a patient with Neurofibromatosis type 1: the diagnostic value of 18F-FDG PET-CT and I-123 MIBG SPECT-CT. J Nucl Med Technol. 2017;46:61\u20132.","journal-title":"J Nucl Med Technol"},{"key":"965_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/S1010-7940(97)00085-7","volume":"12","author":"UU Nkere","year":"1997","unstructured":"Nkere UU, Walter NM. Malignant peripheral nerve sheath tumour: a rare tumour and an unusual intrapericardial presentation. Eur J Cardiothorac Surg. 1997;12:144\u20136.","journal-title":"Eur J Cardiothorac Surg."},{"key":"965_CR25","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev.bi.65.070196.003223","volume":"65","author":"JC Wang","year":"1996","unstructured":"Wang JC. DNA topoisomerases. Annu Rev Biochem. 1996;65:635\u201392.","journal-title":"Annu Rev Biochem."},{"key":"965_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1146\/annurev.pharmtox.41.1.53","volume":"41","author":"TK Li","year":"2001","unstructured":"Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharm Toxicol. 2001;41:53\u201377.","journal-title":"Annu Rev Pharm Toxicol."},{"key":"965_CR27","doi-asserted-by":"publisher","first-page":"15387","DOI":"10.1073\/pnas.242259599","volume":"99","author":"BL Staker","year":"2002","unstructured":"Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr., et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA. 2002;99:15387\u201392.","journal-title":"Proc Natl Acad Sci USA."},{"key":"965_CR28","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1038\/sj.onc.1203622","volume":"19","author":"AR Tee","year":"2000","unstructured":"Tee AR, Proud CG. DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene. 2000;19:3021\u201331.","journal-title":"Oncogene."},{"key":"965_CR29","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1074\/jbc.M113.530303","volume":"289","author":"M Cam","year":"2014","unstructured":"Cam M, Bid HK, Xiao L, Zambetti GP, Houghton PJ, Cam H. p53\/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage. J Biol Chem. 2014;289:4083\u201394.","journal-title":"J Biol Chem."},{"key":"965_CR30","doi-asserted-by":"publisher","first-page":"17414","DOI":"10.1073\/pnas.0809136105","volume":"105","author":"AY Choo","year":"2008","unstructured":"Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA. 2008;105:17414\u20139.","journal-title":"Proc Natl Acad Sci USA."},{"key":"965_CR31","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1158\/2159-8290.CD-14-0159","volume":"4","author":"CF Malone","year":"2014","unstructured":"Malone CF, Fromm JA, Maertens O, DeRaedt T, Ingraham R, Cichowski K. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov. 2014;4:1062\u201373.","journal-title":"Cancer Discov."},{"key":"965_CR32","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1002\/j.1460-2075.1995.tb00257.x","volume":"14","author":"A Haghighat","year":"1995","unstructured":"Haghighat A, Mader S, Pause A, Sonenberg N. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J. 1995;14:5701\u20139.","journal-title":"EMBO J."},{"key":"965_CR33","doi-asserted-by":"publisher","first-page":"4990","DOI":"10.1128\/MCB.15.9.4990","volume":"15","author":"S Mader","year":"1995","unstructured":"Mader S, Lee H, Pause A, Sonenberg N. The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4 gamma and the translational repressors 4E-binding proteins. Mol Cell Biol. 1995;15:4990\u20137.","journal-title":"Mol Cell Biol."},{"key":"965_CR34","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1200\/JCO.2008.20.4495","volume":"27","author":"RG Maki","year":"2009","unstructured":"Maki RG, D\u2019Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009;27:3133\u201340.","journal-title":"J Clin Oncol"},{"key":"965_CR35","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1200\/JCO.2008.20.5054","volume":"27","author":"R Chugh","year":"2009","unstructured":"Chugh R, Wathen JK, Maki RG, Benjamin RS, Patel SR, Meyers PA, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009;27:3148\u201353.","journal-title":"J Clin Oncol."},{"key":"965_CR36","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1002\/cncr.29858","volume":"122","author":"SM Schuetze","year":"2016","unstructured":"Schuetze SM, Wathen JK, Lucas DR, Choy E, Samuels BL, Staddon AP, et al. SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 2016;122:868\u201374.","journal-title":"Cancer."},{"key":"965_CR37","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1093\/annonc\/mdw281","volume":"27","author":"MA Dickson","year":"2016","unstructured":"Dickson MA, Mahoney MR, Tap WD, D\u2019Angelo SP, Keohan ML, Van Tine BA, et al. Phase II study of MLN8237 (Alisertib) in advanced\/metastatic sarcoma. Ann Oncol. 2016;27:1855\u201360.","journal-title":"Ann Oncol."},{"key":"965_CR38","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1101\/gr.144700","volume":"10","author":"WB Barbazuk","year":"2000","unstructured":"Barbazuk WB, Korf I, Kadavi C, Heyen J, Tate S, Wun E, et al. The syntenic relationship of the zebrafish and human genomes. Genome Res. 2000;10:1351\u20138.","journal-title":"Genome Res."},{"key":"965_CR39","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/carcin\/bgr076","volume":"32","author":"C Zhao","year":"2011","unstructured":"Zhao C, Yang H, Shi H, Wang X, Chen X, Yuan Y, et al. Distinct contributions of angiogenesis and vascular co-option during the initiation of primary microtumors and micrometastases. Carcinogenesis. 2011;32:1143\u201350.","journal-title":"Carcinogenesis."},{"key":"965_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/annonc\/mdq338","volume":"22","author":"JR Kroep","year":"2011","unstructured":"Kroep JR, Ouali M, Gelderblom H, Le Cesne A, Dekker TJ, Van Glabbeke M, et al. First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an EORTC soft tissue and bone sarcoma group study. Ann Oncol. 2011;22:207\u201314.","journal-title":"Ann Oncol."},{"key":"965_CR41","doi-asserted-by":"publisher","first-page":"4301","DOI":"10.1158\/1078-0432.CCR-16-2632","volume":"23","author":"JS Nair","year":"2017","unstructured":"Nair JS, Musi E, Schwartz GK. Selinexor (KPT-330) induces tumor suppression through nuclear sequestration of IkappaB and downregulation of survivin. Clin Cancer Res. 2017;23:4301\u201311.","journal-title":"Clin Cancer Res."},{"key":"965_CR42","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/nature19771","volume":"538","author":"J Kim","year":"2016","unstructured":"Kim J, McMillan E, Kim HS, Venkateswaran N, Makkar G, Rodriguez-Canales J, et al. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature. 2016;538:114\u2013117.","journal-title":"Nature."},{"key":"965_CR43","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/bjh.12231","volume":"161","author":"J Etchin","year":"2013","unstructured":"Etchin J, Sanda T, Mansour MR, Kentsis A, Montero J, Le BT, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013;161:117\u201327.","journal-title":"Br J Haematol."},{"key":"965_CR44","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3109\/08880018.2013.767868","volume":"30","author":"R Kebudi","year":"2013","unstructured":"Kebudi R, Cakir FB, Gorgun O, Agaoglu FY, Darendeliler E. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent\/progressive ewing sarcoma family tumors. Pedia Hematol Oncol. 2013;30:170\u20137.","journal-title":"Pedia Hematol Oncol."},{"key":"965_CR45","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/00000421-199412000-00005","volume":"17","author":"SC Blair","year":"1994","unstructured":"Blair SC, Zalupski MM, Baker LH. Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. Am J Clin Oncol. 1994;17:480\u20134.","journal-title":"Am J Clin Oncol."},{"key":"965_CR46","doi-asserted-by":"publisher","first-page":"16981","DOI":"10.18632\/oncotarget.4858","volume":"6","author":"RL Beauchamp","year":"2015","unstructured":"Beauchamp RL, James MF, DeSouza PA, Wagh V, Zhao WN, Jordan JT, et al. A high-throughput kinome screen reveals serum\/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget. 2015;6:16981\u201397.","journal-title":"Oncotarget."},{"key":"965_CR47","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.molcel.2010.10.030","volume":"40","author":"H Cam","year":"2010","unstructured":"Cam H, Easton JB, High A, Houghton PJ. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1alpha. Mol Cell. 2010;40:509\u201320.","journal-title":"Mol Cell."},{"key":"965_CR48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/bjc.2011.498","volume":"106","author":"DC Gilbert","year":"2012","unstructured":"Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer. 2012;106:18\u201324.","journal-title":"Br J Cancer."},{"key":"965_CR49","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1124\/mol.107.034637","volume":"72","author":"A Lansiaux","year":"2007","unstructured":"Lansiaux A, Leonce S, Kraus-Berthier L, Bal-Mahieu C, Mazinghien R, Didier S, et al. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs. Mol Pharmacol. 2007;72:311\u20139.","journal-title":"Mol Pharmacol."},{"key":"965_CR50","volume":"1","author":"J Wang","year":"2014","unstructured":"Wang J, Ye Q, She QB. New insights into 4E-BP1-regulated translation in cancer progression and metastasis. Cancer Cell Microenviron. 2014;1:e331","journal-title":"Cancer Cell Microenviron"},{"key":"965_CR51","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell."},{"key":"965_CR52","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0167-4781(98)00143-2","volume":"1400","author":"J Thompson","year":"1998","unstructured":"Thompson J, Stewart CF, Houghton PJ. Animal models for studying the action of topoisomerase I targeted drugs. Biochim Biophys Acta. 1998;1400:301\u201319.","journal-title":"Biochim Biophys Acta."},{"key":"965_CR53","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s002800050600","volume":"39","author":"CL Erickson-Miller","year":"1997","unstructured":"Erickson-Miller CL, May RD, Tomaszewski J, Osborn B, Murphy MJ, Page JG, et al. Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro. Cancer Chemother Pharmacol. 1997;39:467\u201372.","journal-title":"Cancer Chemother Pharmacol."},{"key":"965_CR54","doi-asserted-by":"publisher","first-page":"365723","DOI":"10.1155\/2013\/365723","volume":"2013","author":"CL Cubitt","year":"2013","unstructured":"Cubitt CL, Menth J, Dawson J, Martinez GV, Foroutan P, Morse DL, et al. Rapid screening of novel agents for combination therapy in sarcomas. Sarcoma. 2013;2013:365723.","journal-title":"Sarcoma."},{"key":"965_CR55","unstructured":"Westerfield M. The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio). 4th ed. Eugene, USA: Univ. of Oregon Press; 2000."},{"key":"965_CR56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.stem.2007.11.002","volume":"2","author":"RM White","year":"2008","unstructured":"White RM, Sessa A, Burke C, Bowman T, LeBlanc J, Ceol C, et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell. 2008;2:183\u20139.","journal-title":"Cell Stem Cell."}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0965-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0965-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41388-019-0965-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:17:21Z","timestamp":1684617441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-019-0965-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,23]]},"references-count":56,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2019,9,26]]}},"alternative-id":["965"],"URL":"https:\/\/doi.org\/10.1038\/s41388-019-0965-5","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,23]]},"assertion":[{"value":"14 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}